Avoro Capital Advisors’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.56B Buy
2,630,000
+23,940
+0.9% +$11.9M 15.34% 1
2025
Q4
$1.27B Buy
2,606,060
+583,838
+29% +$272M 12.48% 1
2025
Q3
$848M Sell
2,022,222
-347,778
-15% -$117M 10.96% 2
2025
Q2
$681M Sell
2,370,000
-305,000
-11% -$91.2M 11.93% 2
2025
Q1
$825M Sell
2,675,000
-85,300
-3% -$29.2M 12.87% 1
2024
Q4
$974M Sell
2,760,300
-98,588
-3% -$36.2M 13.78% 1
2024
Q3
$1.02B Hold
2,858,888
14.94% 1
2024
Q2
$911M Hold
2,858,888
12.13% 1
2024
Q1
$657M Hold
2,858,888
7.66% 1
2023
Q4
$629M Buy
2,858,888
+6,388
+0.2% +$1.47M 8.68% 2
2023
Q3
$644M Sell
2,852,500
-57,499
-2% -$13.2M 10.05% 2
2023
Q2
$642M Buy
2,909,999
+39,999
+1% +$8.86M 8.71% 3
2023
Q1
$643M Buy
2,870,000
+5,000
+0.2% +$1.23M 9.53% 3
2022
Q4
$797M Sell
2,865,000
-61,500
-2% -$15.5M 11.91% 1
2022
Q3
$613M Sell
2,926,500
-43,500
-1% -$9.73M 11.32% 2
2022
Q2
$700M Sell
2,970,000
-60,000
-2% -$12.2M 13.83% 1
2022
Q1
$544M Sell
3,030,000
-5,000
-0.2% -$953K 9.92% 2
2021
Q4
$656M Buy
3,035,000
+35,000
+1% +$6.87M 11.16% 3
2021
Q3
$554M Hold
3,000,000
8.7% 4
2021
Q2
$538M Hold
3,000,000
9.36% 3
2021
Q1
$502M Buy
3,000,000
+150,000
+5% +$25M 8.67% 3
2020
Q4
$433M Buy
+2,850,000
New +$374M 7.45% 3

Other funds holding UTHR

Avoro Capital Advisors's UTHR Position: Q1 2026 in Review

Avoro Capital Advisors increased its United Therapeutics (UTHR) stake by 0.92% in Q1 2026, buying an estimated $11.9M and bringing the position to 2,630,000 shares worth $1.56B. The position accounts for 15.34% of the portfolio, ranked #1.

Avoro Capital Advisors first reported a position in UTHR in Q4 2020 and has held it in 22 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Avoro Capital Advisors held 2,630,000 shares of United Therapeutics worth $1.56B as of Q1 2026.
  • Avoro Capital Advisors bought 23,940 United Therapeutics shares in Q1 2026, an estimated $11.9M.
  • United Therapeutics made up 15.34% of Avoro Capital Advisors's portfolio in Q1 2026, its #1 holding.
  • Avoro Capital Advisors first reported a position in United Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.